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The worldwide prevalence of spinal cord injury (SCI) is estimated to 
be in the range of 223 - 755 per million inhabitants.[1] The incidence 
of SCI is estimated to be 40 - 80 new cases per million per year. 
Between 250 000 and 500 000 people around the world are afflicted 
with a SCI every year.[2]
In South Africa (SA), the incidence of SCI is estimated to be 104 
per million inhabitants,[3] which is well above the global incidence. In 
2017, the incidence in Cape Town was reported to be 75.6 per million 
persons, with the main aetiology being assault, followed by motor 
vehicle accidents (MVAs).[4] Another study in Cape Town reported 
MVAs to be the major cause of SCI.[5]
The primary aim of the healthcare team managing patients with SCI 
is to reduce mortality and morbidity, including complications, and to 
reduce the burden of care by improving patients’ functionality and 
independence.[6,7] The standard principles of treatment of a person 
with SCI entail stabilisation of the injury, prevention of secondary 
injury, surgical decompression and fusion, and rehabilitation.[8] 
Impairments following SCI are loss of motor, sensory and autonomic 
function, including bladder, bowel and sexual function,[8,9] leading 
to loss of participation in normal life activities. These impairments 
are the result of damage to spinal cord axons, loss of neurons, 
the activation of astrocytes and microglia and demyelination and 
degeneration of oligodendrocytes and scarring. [10-13]
Stem cell technologies have opened up the possibility of a potential 
cure for SCI based on the positive motor and functional improvements 
seen in pre-clinical rodent models with spinal cord injury.[13-16] Stem 
cell transplantation in patients with SCI aims to replace impaired 
neurons and oligodendrocytes, to provide trophic support for existing 
(possibly ischaemic) neurons, and to modify the environment within 
the spinal cord to facilitate axonal regrowth. Results in pre-clinical 
studies have begun to translate into human trials, and several 
scientific and ethically approved trials are underway. Some trials have 
demonstrated safe procedural administration of stem cells into the 
spinal cord, i.e. without negative side-effects, but to date neurological 
recovery has been limited.[9,13,17,18] This lack of efficacy is likely to 
be due in part to differences between rodents, larger mammals and 
humans; the nature of the experimental injury induced v. the actual 
traumatic incident; the challenges associated with translating basic 
research findings to the clinic; and insufficient outcome measures 
being utilised during the research. It is well recognised that the 
translation process from basic research to the clinic is long and 
complex.[13,17-20]
The devastating and debilitating result of SCI motivates survivors 
to search for new therapies or cures almost on a continuous basis. 
Following a SCI, these individuals may be willing to pay large 
sums of money for a cure,[9] particularly when their rehabilitation 
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Background. The publicity around stem cell therapy has given many persons who have sustained a devastating injury such as spinal cord 
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participate in the present study. Volunteers who gave written informed consent were asked to complete a biographical questionnaire and 
validated self-report questionnaire (Spinal Cord Independence Measure version III (SCIM III)) before and after their stem cell therapy to 
determine if there were differences in their functional and neurological status. The results of the self-report questionnaires were compared 
with the published expected functional outcome of people with lesions at a similar level of SCI to the participants. The secondary aims of 
the study were to document details of the procedures and their locations, the sources of ‘stem cells’ and the cost.
Results. There was no indication that the participants’ functional outcomes, as measured by the self-reported SCIM III, were better than 
the expected level of functional ability in patients with similar injury levels. Likewise, the neurological motor recovery scored on the 
International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) motor scores showed no improvement post 
stem cell therapy.
Conclusion. This study highlights the need to curb the practice of offering unethical and non-evidence-based stem cell therapy for SCI. 
Ethical research and treatment is encouraged as well as an effective legal framework and education of health professionals, patients and their 
family members and caregivers, which will avoid unrealistic expectations, bogus therapies and the potential adverse effects of non-evidence-
based ‘stem cell therapies’ offered by clinics via the internet.
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professionals cannot offer the recovery they seek. Clinics worldwide 
offer cures on the internet for SCI using what are purported to be 
stem cells.[13,14,21,22] People with SCI, who are desperate for a cure, are 
willing to risk money and health to visit these clinics to be cured,[28] 
in SA and abroad, resulting in so-called stem cell tourism.[13,21-28] The 
interventions[28] are done at great financial cost, despite the lack of 
clinical and statistical evidence that substantiates the claims made 
for a cure. Several organisations have been proactive and invested 
significantly into public/patient education by publishing position 
statements, handbooks and guidelines on the lack of research evidence 
in the use of stem cell therapies for SCI (International Society for Stem 
Cell Research (ISSCR: https://www.closerlookatstemcells.org/) and 
the International Spinal Cord Society (ISCoS: https://www.iscos.org.
uk/)). A warning was issued by the ISSCR against the use of unproven 
stem cell interventions: ‘The ISSCR condemns the administration 
of unproven stem cell-based interventions outside of the context of 
clinical research or medical innovation compliant with the guidelines 
in this document and relevant laws, particularly when it is performed 
as a business activity.’ (http://www.isscr.org/docs/default-source/
all-isscr-guidelines/guidelines-2016/isscr-guidelines-for-stem-cell-
research-and-clinical-translation.pdf?sfvrsn=4). Principles of good 
research, ethical conduct, informed consent and peer review are all 
noted on the website.
Organisations with educational websites for healthcare professionals 
treating people with SCI such as Spinal Cord Injury Rehabilitation 
Evidence (SCIRE:https://scireproject.com/), the American Spinal Cord 
Association (ASIA: https://asia-spinalinjury.org/) and ISCoS (https://
www.iscos.org.uk/), make no reference to stem cell treatment as part 
of the management of SCI. These websites are updated regularly on 
the basis of the most recent research evidence. Much research is being 
conducted but no recommendation on stem cells as a cure for SCI has 
been forthcoming, as the research is still in an early phase.
Possible complications of stem cell therapy include the risk of 
tumour growth (especially if pluripotent cells such as undifferentiated 
embryonic stem cells are used during the procedure)[12,29] and an 
increase in neuropathic pain or allodynia as a result of aberrant 
axonal sprouting.[13,17]
Objective estimation of a patient’s functional recovery after a SCI 
and the assessment of their functional outcome post rehabilitation 
are topics addressed extensively in the literature.[13,30-35] As a reaction 
to the trend that patients seek stem cell interventions despite the 
lack of research evidence in humans (including clinical trials that 
are still in early phases), a survey on persons living in South Africa 
who had undergone ‘stem cell therapy’ was undertaken to determine 
whether the therapy had had an influence on their level of motor 
impairment and functional ability.[13,30,36,37] The primary aim of the 
present study was therefore to perform a critical analysis of the level 
of motor impairment and functional ability measured on the Spinal 
Cord Independence Measure (SCIM) III in people with SCI who 
had undergone ‘stem cell therapy’.[32,33] The secondary aims were to 
document details of the procedures and their locations, sources of 
‘stem cells’ and cost.
Methodology
Statement of ethical conduct
Approval was obtained from the Research Ethics Committee of 
the Faculty of Health Sciences, University of Pretoria (ref number 
S5/2010). Approval from the CEO of the Quadpara Association 
of South Africa (QASA) was obtained to use their membership 
email list. Each participant gave written informed consent before 
completing the questionnaires.
Recruitment
Participants in the survey were recruited from persons with SCI who 
had received rehabilitation at a well-known rehabilitation centre, 
where one of the authors (MS) is employed as a physiotherapist 
and where the participants asked to receive rehabilitation after 
receiving stem cell therapy. Participants were also recruited from 
QASA’s membership list. Inclusion criteria were: (i) people with SCI 
living in SA who had received stem cell therapy in SA or abroad; 
(ii) people with SCI who had received stem cell therapy and who 
had received their rehabilitation at a rehabilitation centre or unit or 
practice in SA; (iii) people with SCI who were willing to participate 
voluntarily in the study and had given their informed consent; and 
(iv) participants over the age of 18 with SCI and who were otherwise 
in good health.
All persons with SCI who, after having received stem cell therapy, 
requested rehabilitation at the rehabilitation centre, gave consent 
for their data to be used in this research project. QASA members 
were also emailed and asked to participate in the study if they had 
received stem cell therapy. Other rehabilitation units throughout 
SA were asked to recruit volunteers amongst persons who had 
undergone stem cell therapy. All volunteers who responded were 
included in the research. Respondents who expressed an interest in 
receiving stem cell therapy, but had not received any, were excluded 
from the study.
Participants who volunteered to participate in the study were 
requested to complete a biographical questionnaire and the SCIM 
III functional outcomes measure retrospectively after receiving 
stem cell therapy and subsequent rehabilitation. Participants also 
had to give permission that their ISNCSCI scores could be accessed 
from their pre-stem cell therapy patient records at discharge from 
their initial rehabilitation.
The functional ability of people who sustain a SCI is not 
accurately estimated by a neurological examination alone;[36] 
therefore participants’ functional ability was assessed by scoring 
the activities of daily living using the SCIM III outcomes measure.[32,33] 
The SCIM III is a standardised rating scale reflecting the level of 
independence (participation) in activities of the person with a 
SCI in daily life such as mobility, self-care, sphincter control and 
respiratory function.[32,33,37] In this study, the self-report version 
of the SCIM III in which participants had to assess their own 
functional ability, was used. The self-report version of the SCIM III 
has previously been validated. [32,33,38] The participants’ self-reported 
SCIM III scores were compared with the published SCIM scores of 
lesions at various levels of the spinal cord.[35,36]
Results
Eleven persons with SCI who had received ‘stem cell therapy’ 
volunteered to participate in the study (Table 1). Owing to the 
large differences in the nature of the participants’ injuries and 
the treatments they had received, the results are presented as 
descriptive statistics.
Participants indicated that their expectation of the stem cell 
therapy was to gain any improvement in the function that they lost 
or which had been compromised owing to their SCI.  Expectations 
specifically stated were: higher functional ability related to 
improvement in hand function, walking, and improvement in 
bladder and bowel function.
Participants reported that the reason for considering stem 
cell therapy was based on the positive reports obtained from the 
internet or from information received from family and friends. 
Participants received their ‘stem cell therapy’ between 14 days and 
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8 years post SCI. The outcomes can therefore not be compared 
between participants.
The type of stem cell therapy that participants received is 
displayed in Table 2. The procedure at the various centres consulted 
by the participants differed, but all centres recommended at least 3 
months of intensive rehabilitation post stem cell therapy.
Participants’ self-reported SCIM III scores were compared with 
the published SCIM III scores of patients with a lesion at the 
Table 1. Biographical data of participants
Subject Age (years) Gender SCI type Cause Level of injury Time between SCI and stem cell therapy
1 51 M Para ASIA A GSW T5 5 years
2 36 M Tetra ASIA A GSW C8/T1 8 years
3 39 M Para ASIA A GSW T5 14 days
4 38 F Tetra ZPP MBA C6/7 1 year
5 38 F Tetra ASIA A Fall C4/5 6 years
6 43 M Tetra ZPP MVA C5 7 years
7 42 M Tetra ASIA A MVA C6/7 2 years
8 30 M Tetra ASIA B MVA C6/7 9 months
9 47 M Para ASIA A MVA T12/L1 4 years
10 27 M Tetra ASIA A QUAD C6/7 2.5 years
11 22 F Para ZPP QUAD T5 3 years
Mean = 36.9 8 M 3 F
4 Para
7 Tetra
4 - C6/7, 2 - T5
1 - C4/5, 1  - C5
1 - C8/T1, 1- T12/
L1 Mean = 3.6 years
ASIA = American Spinal Injury Association classification for spinal cord injury; Para = paraplegic; Tetra = tetraplegic; T = thoracic; C = cervical; ZPP = zone of partial preservation (muscles and 
skin innervated below the lesion in the complete SCI); MVA = motor vehicle accident; QUAD = quad bike accident; GSW = gunshot wound.
Table 2. Nature of the stem cell treatment
Subject Nature of stem cells Delivery mode
Country of 
treatment
Pre-stem cell 
treatment at place of 
administration
Post-stem cell treatment 
recommended
1 Autologous Lumbar puncture India Nonspecific Rehabilitation
2 Sheep Subcutaneous/intramuscular 
injection
South Africa Nonspecific Rehabilitation, weekly stem 
cell injection and stem cell 
tablets
3 Rabbit Subdural injection during 
spinal surgery
South Africa Nonspecific Homeopathic tablets, 
rehabilitation
4 Rabbit Lumbar puncture, injections 
into abdomen
Germany Detox, ozone therapy Rehabilitation, 
multivitamins
5 Rabbit Four injections on stomach, 
one into spinal cord, one on 
each hip
Germany One week ozone 
therapy, Lipoten drip
Rehabilitation, drips, 
vit B12
6 Sheep Subcutaneous or 
intramuscular injections into 
back and neck
South Africa Nonspecific Rehabilitation, weekly 
injections
7 Unknown Intravenous injection Holland Nonspecific Rehabilitation
8 Fetal Intravenously in saline 
solution. Also injected into 
subcutaneous tissue around 
back of neck
Holland Nonspecific Physiotherapy and 
rehabilitation
9 Rabbit Multiple injections Germany Detox and preparation 
medicine
Rehabilitation
10 Fetal Lumbar puncture after 
drainage of  syrinx in spinal 
cord
China Traditional 
Chinese medicine, 
acupuncture, IV drip 
to boost stem cells
Physiotherapy 2×/day, 
stretches more than 
strengthening exercises: 
arms and legs
11 Fetal stem cells Lumbar puncture after surgery China Traditional 
Chinese medicine, 
acupuncture, IV drip 
to boost stem cells
Physiotherapy 2×/day, 
stretches more than 
strengthening exercises: 
arms and legs, rehabilitation
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same level[35] (Fig. 1).The actual scores are 
presented in Table 3. In Fig. 1, it can be 
observed that 6 of the participants had 
not reached the expected functional level 
on the SCIM III related to their SCI level 
before the stem cell therapy.[35] Four of 
the participants’ SCIM III scores remained 
unchanged pre and post stem cell therapy.
Only 1 of the 11 participants exceeded the 
maximum SCIM III score for her lesion level, 
which may be ascribed to zones of partial 
preservation (ZPP). The same participant’s 
function did, however, not improve after 
the stem cell therapy and rehabilitation. 
Based on the qualitative feedback which 
participants gave, participant no. 11 walked 
with crutches and an ankle-foot orthosis 
(AFO) 20% of the time pre stem cell therapy. 
Post stem cell therapy she had to use a 
full calliper on her weaker leg owing to 
diminished sensation and muscle control, 
and could only walk with a calliper and 
crutches under supervision for an hour a 
day. The participant’s pain at the level of 
the lesion improved post stem cell therapy. 
At the stem cell therapy centre where she 
received the procedure, she was told that scar 
tissue was removed during surgery for the 
stem cell therapy. However, a year following 
the procedure, the pain had increased to the 
pre-surgery level.
One participant’s SCIM III score (no. 1) 
decreased by 10 points post-stem cell 
therapy because he had to change from clean 
intermittent self-catheterisation (CISC) to 
an indwelling catheter. One participant’s 
SCIM III score (no. 5) improved by one point 
during the rehabilitation period post-stem 
cell therapy and then returned to the lower 
level of function prior to stem cell therapy, 
once he was home again. Participant no. 3 
underwent his stem cell therapy 2 weeks 
after his injury and had had no rehabilitation 
prior to stem cell therapy. Following the 
rehabilitation programme, he showed a gain 
in SCIM III score of 36, but did not reach his 
expected SCIM III score for his lesion post 
rehabilitation.
Five participants’ SCIM III scores 
improved post stem cell therapy and 
rehabilitation. Three of these participants 
sustained C6/7 lesions. Two of the 3 patients, 
both of whom had ZPP, achieved better than 
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Fig. 1. Comparison of participants’ SCIM III scores pre and post stem cell therapy. (ZPP = zone of 
partial preservation (muscles and skin innervated below the lesion in the complete SCI); SCIM = Spinal
Cord Independence Measure.)
Table 3. SCIM III scores in participants’ pre- and post-stem cell therapy compared with the functional level of persons with similar 
spinal cord injuries
Subject 
no.
Level of 
injury
Pre-stem cell 
therapy 
Post-stem 
cell therapy Current 
Expected for 
injury level[37] Maximum[37]
Participant’s 
change in 
score
Expected 
change during 
acute rehab[37]
Expected change 
during  post-
acute rehab[37]
1 T5 63 63 53 63 69 -10 30.5 5.5
2 C8 51 51 51 42 69 0 25 7
3 T5 23 pre rehab 59 59 63 69 36 30.5 5.5
4 C6/7 ZPP 24 45 49 43.5 66 25 7 7
5 C4 16 17 16 19 36.5 1 12 0
6 C6/7 ZPP 45 50 50 43.5 66 5 7 7
7 C6 13 23 26 43.5 66 13 28 9
8 C6 24 24 24 43.5 66 0 28 9
9 T12 66 66 66 67.5 76 0 34 6
10 C7 45 45 46 43.5 66 1 7 7
11 T5 ZPP 78 78 78 63 69 0 30.5 5.5
Average 6 22 6
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expected SCIM III scores but did not reach 
the maximum SCIM III score reported for 
their lesion level. Five participants achieved 
higher than expected SCIM III scores but 2 
of these (no. 11 and no. 2) had no change in 
SCIM III score after the stem cell therapy. 
On average, the participants’ SCIM III scores 
improved by 6 points, which is to be expected 
during post-acute rehabilitation.[30,39]
Participants’ ISNCSCI motor score 
changes are presented in Table 4. Four of 
the 11 participants’ ISNCSCI motor scores 
stayed the same pre and post stem cell 
therapy. Three participants’ scores improved 
between 2 and 5 scores post stem cell 
therapy. Reasons for the improvement in 
ISNCSCI motor scores were ascribed to 
gains in muscle strength in the muscles that 
were innervated pre stem cell therapy; no 
impaired myotomes, pre stem cell therapy, 
were re-innervated post stem cell therapy. 
One participant’s ISNCSCI motor score 
decreased by 1 point post stem cell therapy 
even after rehabilitation. She had to use a 
calliper instead of just an AFO and crutches 
post stem cell therapy.
Fig. 2 shows the participants’ level of mobility. 
Of the 11 participants, all used either a power 
or a manual wheelchair for more than 90% of 
the time. Two participants used therapeutic 
walking with assistance and assistive devices 
but were not functional walkers in their 
communities. Fig. 3 presents bowel and 
bladder management post stem cell therapy. 
All 11 participants had neurogenic bowels 
and used a bowel programme, and all except 
one needed assistance with their bowel 
programme. Eight participants had indwelling 
catheters and 3 did CISC, which indicates that 
none had normal bladder function. These 
results show no improvement from the pre-
stem cell mobility scores.
Participants’ financial expenses for 
receiving stem cell therapy and travel are 
summarised in Table 5.
Discussion
None of the stem cell treatments advertised 
to cure SCI resulted in an improvement 
in function measured on the SCIM III 
beyond the expected function for the level 
of injury as measured after traditional 
recognised rehabilitation programmes, nor 
did motor scores improve below the pre- 
stem cell treatment neurological level of 
injury. No increased myotome innervation 
was observed, as shown by the available 
ISNCSCI motor scores. No change in 
bladder or bowel function was reported, 
nor did the participants’ mobility improve. 
The improvement experienced by the 
participants was most likely brought about 
by the rehabilitation given post stem cell 
therapy and not by neural regeneration. Six 
of the 11 participants had not reached the 
expected level of functional outcome for the 
level of their lesions. Post stem cell therapy 
results such as loss of sensation, increased 
pain, decreased function, and increased use 
of assistive devices are not indicative of 
effective therapy. These results may in fact 
reflect a detrimental effect owing to the stem 
cell therapy received.
Powered wheelchair 90% of the time
Manual wheelchair 90% of time
Some therapeutic walking
Walking
0          1         2         3         4         5         6         7         8         9        10
Number of participants, %
Fig. 2. Mobility outcomes.
Table 4. Muscle strength and changes in ASIA scores
Subject
Pre stem cell 
therapy – ASIA
Post stem cell 
therapy – ASIA
Any gain in muscle 
innervation post 
stem cell therapy? 
Participant’s perception of 
new muscle strength post 
stem cell therapy
Current problems post stem 
cell therapy
1 50 50 No Not stronger Went from self catheterisation 
to suprapubic catheter 
Severe neurogenic pain and 
constipation
2 44 44 No Not stronger Spasms
3 50 50 No Not stronger None
4 22 27 no new 
myotomes
No Yes, stronger from rehab
5 6 8 No Yes,stronger from rehab Severe neurogenic pain in 
hands, spasms
6 None No better No Not stronger
7 None No better No Not stronger Lioresal pump for spasm
8 None No better No Not stronger
9 50 50 No Yes, stronger from rehab
10 20 24 no new 
myotomes
No Yes, stronger from rehab Spasms and neurogenic pain
11 62 61 No, and loss of 
sensation
Now needs calliper instead of 
AFO to walk
Unable to walk as well post 
stem cell therapy owing to 
decreased sensation
ASIA = American Spinal Injury Association classification for SCI; AFO = ankle-foot orthosis.
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Ethically approved and scientific evidence-
based trials are being conducted to assess 
safety and changes in functional ability post SCI, 
but most are phase I and II trials.[12,13,18] Before 
stem cell therapy can become a recognised 
form of treatment for SCI, the outcome of 
well-controlled clinical trials is awaited, and 
the use of unproven therapies such as those 
reported herein, are discouraged. [13,28]
The stem cell treatments received, both 
within SA and abroad, were not administered 
by recognised spinal cord injury treatment 
centres or recommended by such, and were 
all sourced via the internet or by word 
of mouth from other patients and their 
families. The stem cell tourism trend[13,22,27,28] 
shows that vulnerable people with SCI are 
willing to undergo non-evidence-based 
procedures in the hope of achieving a cure.
Using the keywords ‘Stem cells for SCI’, a 
Google search on 8 October 2018 resulted 
in 8 080 000 hits. ‘Stem cell therapy’ websites 
are found to be anecdotal in nature, with 
questionable scientific credibility.[13,28] As 
stem cell therapy is still in the experimental 
phase, it should only be administered as 
part of a recognised, ethically approved 
clinical trial, and it should not require that 
participants pay for the procedure.
The costs incurred as a result of the 
stem cell therapy and travel, with no clinical 
evidence of improvement, raises ethical 
concerns regarding people who are in a 
vulnerable state being susceptible to emotional 
and financial exploitation. The ISSCR task 
force has developed the Guidelines for the 
Clinical Translation of Stem Cells (http://
www.isscr.org/docs/default-source/all-isscr-
guidelines/guidelines-2016/isscr-guidelines-
for-stem-cell-research-and-clinical-translation.
pdf?sfvrsn=4). This document highlights 
the core principles that should guide the 
responsible translation of basic stem cell 
research into appropriate clinical applications. 
The dangers of using non-evidence-based 
stem cell treatment are summarised on the 
ISSCR website as follows: ‘The premature 
commercialization of unproven stem cell 
treatments, and other cell-based interventions 
inaccurately marketed as containing or acting 
on stem cells, not only puts patients at risk 
but also represents one of the most serious 
threats to the stem cell research community, 
as it may jeopardize the reputation of the 
field and cause confusion about the actual 
state of scientific and clinical development. 
Government authorities and professional 
organizations are strongly encouraged to 
establish and strictly enforce regulations 
governing the introduction of stem cell-based 
medical interventions into commercial use.’
The International Campaign for Cure for 
Spinal Cord Paralysis (ICCP) has compiled 
guidelines to enable people with SCI who 
consider participation in clinical trials to 
make an informed decision regarding stem 
cell therapy.[30] The ICCP position statement 
on cell-based therapies warns people of the 
risks of partaking in non-evidence-based 
therapies, both for the sake of the participant 
and for the future of research in the field. 
Participation in a clinical trial without 
ethical approval could limit or disqualify 
the participant from participating in future 
ethically approved trials.
In the critical analysis of the outcomes 
of persons who received stem cell therapy 
after a SCI, there is no evidence that any 
of the so-called stem cell procedures that 
participants underwent were beneficial. 
With regard to the participants who did 
experience an improvement in muscle 
strength and function, this appeared to be 
in muscles that were innervated prior to the 
therapy, as a result of neural plasticity and 
compensation from the rehabilitation, rather 
than restoration of spinal cord function.[40] 
People with SCI should therefore be warned 
that bogus therapies[41,42] exist and should 
be discouraged from undergoing treatment 
with these therapies after sustaining a SCI.
Regarding the legislation that deals 
with stem cell therapy,[43] Chapter 8 of the 
National Health Act (no. 61 of 2003),[44] 
the Medicines and Related Substances 
Act (no. 101 of 1965),[45] the Consumer 
Protection Act (no. 68 of 2008)[46] and the 
Health Professions Council of South Africa’s 
ethical codes regarding good practice, over-
servicing, perverse incentives and related 
matters as well as biotechnology research[47] 
are available to all health professionals and 
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Fig. 3. Bladder and bowel management.
Table 5. Financial cost incurred by participants who received stem cell therapy
Subject no.
Cost of stem cell 
therapy (ZAR) Cost of travel (ZAR)
Total treatment 
cost (ZAR)
1 150 000 36 000 186 000
2 Free Not specified N/A
3 150 000 60 000 210 000
4 80 000 89 000 169 000
5 86 200 93 220 179 320
6 Free 11 200 11 200
7 76 000 71 000 142 000
8 70 000 25 000 95 000
9 150 000 Not sure 150 000
10 650 000 50 000 700 000
11 325 000 71 000 396 000
Total 1 737 200 506 420 2 238 520
Average 157 927 56 268 203 501
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regulators. No action has thus far been taken against professionals 
providing unproven stem cell treatments to persons with SCI in SA.
Limitations of the present study include the small number of 
voluntary participants that could be recruited. This may be due to 
the fact that participants did not want to reveal the cost and poor 
outcomes of their stem cell therapy. Since this study was concluded, 
the first author has encountered additional persons with SCI who 
have undergone stem cell therapy in SA, with a similar lack of positive 
results.
This study underlines the need for effective legislation and an 
effective means of law enforcement to guard consumers against 
exploitation by providers of non-evidence-based therapies. An 
information booklet compiled by Master et al. can be downloaded to 
assist people who have sustained a SCI, and their families and friends, 
regarding stem cells and their use (http://www.amc.edu/academic/
bioethics/documents/SCPatientBookletFeb_2014.pdf).[28]
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